Company · TMCI
Treace Medical Concepts, Inc.
Name as listed on its exchange; filed with the SEC as TREACE MEDICAL CONCEPTS, INC.
Nasdaq's symbol directory lists TMCI on Nasdaq as “Treace Medical Concepts, Inc. - Common Stock”.
In the 12 months to Nov 8, 2026: insiders bought on 3 occasions ($247K); 2 filings by holders of 5% or more; 1 company report (Form 8-K, since May 26, 2026).
Insider trades · SEC Form 4
Those inside the hall
Open-market purchases and sales only. Legs one person filed for one day are combined.
Who traded
- John T. Treace, Chief Executive Officer bought $247K
Every trade (3)
- BUYJohn T. Treace, Chief Executive Officer bought $48K
- BUYJohn T. Treace, Chief Executive Officer bought $22K
- BUYJohn T. Treace, Chief Executive Officer bought $177K
Large holders · SEC Schedules 13D and 13G
Five percent and over
Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G
- Armistice Capital, LLC 9.79%
- John T. Treace 19.2%
Company reports · SEC Form 8-K
In its own words
Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.
- Results of operations and financial condition Nov 6, 2026
Sources: SEC EDGAR (Forms 4, 144 and 8-K) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.